We have adjusted our forecasts to reflect strength in Health growth and medium term investment support for the unit. We have also taken down our Signal assumptions given the increasing likelihood of Brexit caution related impact. The net effect is that while 2018 EPS only falls 1.4%, 2019 and 2020 EPS fall 7.1% and 7.4% respectively. Earnings growth is now an uninspiring 2.3% for 2019. We cut out Target Price to 136p resulting in a Hold rating (cut from Buy). Long term investors interested in He ....
